Acute Methylenedioxypyrovalerone Toxicity

Journal of Medical Toxicology

Volumn 11, Issue 2, 2015, Pages 185-194

  Froberg, Blake A ^a,k   Levine, Michael ^b,c   Beuhler, Michael C ^d   Judge, Bryan S ^e   Moore, Philip W ^f   Engebretsen, Kristin M ^g   Mckeown, Nathanael J ^h   Rosenbaum, Christopher D ⁱ   Young, Amy C ^j   Rusyniak, Daniel E ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

^f Pinnacle Health System   (United States)

^g REGIONS HOSPITAL   (United States)

^h PORTLAND VA MEDICAL CENTER   (United States)

ⁱ TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k Pediatrics and Emergency Medicine   (United States)

more..

Author keywords

Central nervous system stimulants; Designer drugs; Drug effects; Poisons; Street drugs; Toxicology

Indexed keywords

4' METHYLMETHCATHINONE; ADRENERGIC RECEPTOR STIMULATING AGENT; BENZODIAZEPINE DERIVATIVE; CATHINONE; CENTRAL STIMULANT AGENT; DESIGNER DRUG; DIAZEPAM; HALOPERIDOL; LORAZEPAM; METHCATHINONE; METHYLENEDIOXYPYROVALERONE; METHYLONE; MIDAZOLAM; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; STREET DRUG; UNCLASSIFIED DRUG; VECURONIUM; ZIPRASIDONE; 1,3 BENZODIOXOLE DERIVATIVE; 3,4-METHYLENEDIOXYPYROVALERONE; ALKALOID; HYPNOTIC SEDATIVE AGENT; PYRROLIDINE DERIVATIVE;

ACIDOSIS; ADOLESCENT; ADULT; AGITATION; ARTICLE; CLINICAL ARTICLE; DRUG ABUSE; DRUG EFFECT; DRUG EXPOSURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTUBATION; MALE; MASS FRAGMENTOGRAPHY; MENTAL HEALTH CARE; NONHUMAN; PATIENT CARE; RETROSPECTIVE STUDY; TACHYCARDIA; TANDEM MASS SPECTROMETRY; TOXICITY; AGE; HUMAN; MIDDLE AGED; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGY; REGISTER; RESTLESSNESS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; ALKALOIDS; BENZODIOXOLES; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; LORAZEPAM; MALE; MIDDLE AGED; PSYCHOMOTOR AGITATION; PYRROLIDINES; REGISTRIES; RETROSPECTIVE STUDIES; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84931566215     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-014-0446-8     Document Type: Article

References (42)

1. Nencini P, Ahmed AM. Khat consumption: a pharmacological review. Drug Alcohol Depend. 1989;23(1):19–29.
2. Westphal F, Junge T, Rosner P, Sonnichsen F, Schuster F. Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: a designer drug with alphapyrrolidinophenone structure. Forensic Sci Int. 2009;190(1–3):1–8.
3. Brandt SD, Sumnall HR, Measham F, Cole J. Analyses of second-generation ‘legal highs’ in the UK: initial findings. Drug Test Anal. 2010;2(8):377–82.
4. Dargan PI, Albert S, Wood DM. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM. 2010;103(11):875–9.
5. Ojanpera IA, Heikman PK, Rasanen IJ. Urine analysis of 3,4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography–mass spectrometry. Ther Drug Monit. 2011;33(2):257–63.
6. Emerson TS, Cisek JE. Methcathinone: a Russian designer amphetamine infiltrates the rural midwest. Ann Emerg Med. 1993;22(12):1897–903.
7. Bronstein AC, Spyker DA, Cantilena Jr LR, Green JL, Rumack BH, Dart RC. 2010 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila). 2011;49(10):910–41.
8. DAWN. “Bath salts” were involved in over 20,000 drug-related emergency department visits in 20112013 Sept. 17, 2013.
9. Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin Toxicol (Phila). 2011;49(6):499–505.
10. Aarde SM, Huang PK, Creehan KM, Dickerson TJ, Taffe MA. The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. Neuropharmacology. 2013;71:130–40.
11. Brenneisen R, Fisch HU, Koelbing U, Geisshusler S, Kalix P. Amphetamine-like effects in humans of the khat alkaloid cathinone. Br J Clin Pharmacol. 1990;30(6):825–8.
12. Simmler LD, Wandeler R, Liechti ME. Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence. BMC Res Notes. 2013;6:220.
13. Baumann MH, Partilla JS, Lehner KR, et al. Powerful cocainelike actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology. 2013;38(4):552–62.
14. Emergency department visits after use of a drug sold as “bath salts”—Michigan, November 13, 2010-March 31, 2011. MMWR Morb Mortal Wkly Rep. 2011;60(19):624–7.
15. Kesha K, Boggs CL, Ripple MG, et al. Methylenedioxypyrovalerone (“bath salts”), related death: case report and review of the literature. J Forensic Sci. 2013;58(6):1654–9.
16. Thornton SL, Gerona RR, Tomaszewski CA. Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J Med Toxicol. 2012;8(3):310–3.
17. Borek HA, Holstege CP. Hyperthermia and multiorgan failure after abuse of “bath salts” containing 3,4-methylenedioxypyrovalerone. Ann Emerg Med. 2012;60(1):103–5.
18. Murray BL, Murphy CM, Beuhler MC. Death following recreational use of designer drug “bath salts” containing 3,4-methylenedioxypyrovalerone (MDPV). J Med Toxicol. 2012;8(1):69–75.
19. Mugele J, Nanagas KA, Tormoehlen LM. Serotonin syndrome associated with MDPV use: a case report. Ann Emerg Med. 2012;60(1):100–2.
20. Levine M, Levitan R, Skolnik A. Compartment syndrome after “bath salts” use: a case series. Ann Emerg Med. 2013;61(4):480–3.
21. Adamowicz P, Gil D, Skulska A, Tokarczyk B. Analysis of MDPV in blood—determination and interpretation. J Anal Toxicol. 2013;37(5):308–12.
22. Wright TH, Cline-Parhamovich K, Lajoie D, Parsons L, Dunn M, Ferslew KE. Deaths involving methylenedioxypyrovalerone (MDPV) in Upper East Tennessee. J Forensic Sci. 2013;58(6):1558–62.
23. Wyman JF, Lavins ES, Engelhart D, et al. Postmortem tissue distribution of MDPV following lethal intoxication by “bath salts”. J Anal Toxicol. 2013;37(3):182–5.
24. Warrick BJ, Hill M, Hekman K, et al. A 9-state analysis of designer stimulant, “bath salt”, hospital visits reported to poison control centers. Ann Emerg Med. 2013;62(3):244–51.
25. Wax PM, Kleinschmidt KC, Brent J. The Toxicology Investigators Consortium (ToxIC) Registry. J Med Toxicol. 2011;7(4):259–65.
26. Wood DM, Greene SL, Dargan PI. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J. 2011;28(4):280–2.
27. Schulden JD, Lopez MF, Compton WM. Clinical implications of drug abuse epidemiology. Psychiatr Clin N Am. 2012;35(2):411–23.
28. Young AC, Schwarz ES, Velez LI, Gardner M. Two cases of disseminated intravascular coagulation due to “bath salts” resulting in fatalities, with laboratory confirmation. Am J Emerg Med. 2013;31(2):445 e3–5.
29. Gowing LR, Henry-Edwards SM, Irvine RJ, Ali RL. The health effects of ecstasy: a literature review. Drug Alcohol Rev. 2002;21(1):53–63.
30. Roberts JR, Greenberg MI. Cocaine washout syndrome. Ann Intern Med. 2000;132(8):679–80.
31. Hall AH, Kulig KW, Rumack BH. Intravenous epinephrine abuse. Am J Emerg Med. 1987;5(1):64–5.
32. Benowitz NL, Osterloh J, Goldschlager N, Kaysen G, Pond S, Forhan S. Massive catecholamine release from caffeine poisoning. JAMA. 1982;248(9):1097–8.
33. Falgiani M, Desai B, Ryan M. “Bath salts” intoxication: a case report. Case Rep Emerg Med. 2012;2012:976314.
34. Boulanger-Gobeil C, St-Onge M, Laliberte M, Auger PL. Seizures and hyponatremia related to ethcathinone and methylone poisoning. J Med Toxicol. 2012;8(1):59–61.
35. Ross EA, Reisfield GM, Watson MC, Chronister CW, Goldberger BA. Psychoactive “bath salts” intoxication with methylenedioxypyrovalerone. Am J Med. 2012;125(9):854–8.
36. Macher AM, Penders TM. False-positive phencyclidine immunoassay results caused by 3,4-methylenedioxypyrovalerone (MDPV). Drug Test Anal. 2013;5(2):130–2.
37. Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use. J Emerg Med. 2003;24(4):369–73.
38. Chakko S, Sepulveda S, Kessler KM, et al. Frequency and type of electrocardiographic abnormalities in cocaine abusers (electrocardiogram in cocaine abuse). Am J Cardiol. 1994;74(7):710–3.
39. Ross EA, Watson M, Goldberger B. “Bath salts” intoxication. N Engl J Med. 2011;365(10):967–8.
40. Wood DM, Davies S, Greene SL, et al. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol (Phila). 2010;48(9):924–7.
41. Benzie F, Hekman K, Cameron L, Wade DR, Miller C, Smolinske S, Warrick B. Seizures associated with synthetic cathinone exposures in the pediatric population. Pediatr Neurol. 2014;51(1):67–70.
42. Schifano F, Corkery J, Ghodse AH. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, “meow meow”) in the United Kingdom. J Clin Psychopharmacol. 2012;32(5):710–4.